Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
Healthy Volunteers
NCT06659640

A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Led by Alnylam Pharmaceuticals · Updated on 2026-05-14

120

Participants Needed

16

Research Sites

189 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to: * evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers * evaluate the efficacy, safety, tolerability and PD of multiple doses of ALN-6400 in adult patients with HHT

CONDITIONS

Official Title

A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Part A: Healthy adult volunteers
  • Part B: Adult patients with a clinical diagnosis of Hereditary Hemorrhagic Telangiectasia (HHT)
Not Eligible

You will not qualify if you...

  • Part A: Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above the upper limit of normal (ULN)
  • Part A: Known infection with HIV, or current or chronic hepatitis C or B virus
  • Part A: Estimated glomerular filtration rate (eGFR) below 90 mL/min/1.73m² at screening
  • Part B: ALT or AST levels greater than 2 times ULN
  • Part B: Total bilirubin greater than 1.5 times ULN
  • Part B: eGFR below 30 mL/min/1.73m² at screening
  • Parts A and B: Unwillingness to comply with contraceptive requirements during the study period
  • Other protocol defined inclusion/exclusion criteria apply

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 16 locations

1

Clinical Trial Site

Birmingham, Alabama, United States, 35233

Actively Recruiting

2

Clinical Trial Site

Cypress, California, United States, 90630

Actively Recruiting

3

Clinical Trial Site

Gainesville, Florida, United States, 32608

Actively Recruiting

4

Clinical Trial Site

Indianapolis, Indiana, United States, 46260

Actively Recruiting

5

Clinical Trial Site

Boston, Massachusetts, United States, 02114

Actively Recruiting

6

Clinical Trial Site

Rochester, Minnesota, United States, 55905

Actively Recruiting

7

Clinical Trial Site

St Louis, Missouri, United States, 63110

Actively Recruiting

8

Clinical Trial Site

Chapel Hill, North Carolina, United States, 27514

Actively Recruiting

9

Clinical Trial Site

Camperdown, Australia, 2050

Actively Recruiting

10

Clinical Trial Site

Parkville, Australia, 3050

Actively Recruiting

11

Clinical Trial Site

Mount Royal, Canada, H3P 3P1

Actively Recruiting

12

Clinical Trial Site

Toronto, Canada, M5B 1W8

Actively Recruiting

13

Clinical Trial Site

Bordeaux, France, 33000

Actively Recruiting

14

Clinical Trial Site

Bron, France, 69500

Actively Recruiting

15

Clinical Trial Site

Homburg, Germany, 66421

Actively Recruiting

16

Clinical Trial Site

L'Hospitalet de Llobregat, Spain, 8907

Actively Recruiting

Loading map...

Research Team

A

Alnylam Clinical Trial Information Line

CONTACT

A

Alnylam Clinical Trial Information Line

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | DecenTrialz